It's TimeNow the AGM has come and gone I think Replicel will begin to roll out the game plan for 2021.
The deal with Mainpointe should be completed in the next week or so and submitted for TSXV approval. Once this is done the money should begin to flow into Replicel. It sounds like it has taken a bit longer for these preliminary steps than first announced (Nov. 11th NR).
Once the money is in place I assume we will hear a more detailed description of how the Dermal injector will be tested and subsequently the FDA application.
We should then see some larger investors especially in the U.S. who have been waiting to see if this device is the real deal. Presently all we are seeing is daytrading which will take the share price nowhere. We need some large volume to push through this daytrading wall.